Skip to content

The effects of tadalafil and serteraline cobmination therapy in treatment of premature ejaculation

Comparison of the effects of tadalafil and serteraline cobmination therapy with serteraline and placebo in treatment of premature ejaculation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138811101853N7
Enrollment
102
Registered
2012-09-15
Start date
2012-04-29
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature ejaculation. Premature ejaculation

Interventions

Intervention 1: Sertraline 50 mg daily with tadalafil 10 mg before intercourse. Intervention 2: Sertraline 50 mg daily with placebo before intercourse.
Treatment - Drugs
Placebo
Sertraline 50 mg daily with tadalafil 10 mg before intercourse
Sertraline 50 mg daily with placebo before intercourse

Sponsors

Urology Research Center
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: People who have been married at least for 6 months; Patients who suffer from primary premature ejaculation (PE); Age between 50-18 years Exclusion criteria: A history of mental illness and physical illness such as liver disease and diabetes Mellitus (DM); Previous surgery on sexual function was affected; Currently abusing alcohol or drug; Patients with secondary PE associated with erectile dysfunction (ED); Contraindications of taking PDEIs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The time from penetration to ejaculation. Timepoint: before and the end of the study. Method of measurement: timer.

Secondary

MeasureTime frame
Control over ejaculation. Timepoint: before and the end of the study. Method of measurement: PEP questionnaire.;Satisfaction. Timepoint: before and the end of the study. Method of measurement: PEP questionnaire.;Distress. Timepoint: before and the end of the study. Method of measurement: PEP questionnaire.;Problem with partner. Timepoint: before and the end of the study. Method of measurement: PEP questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Reza Shahrokhi

Urology Research Center

urc@gums.ac.ir+98 13 1552 5259

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026